louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06948630: Hemogram Parameter Changes With Sepsis Filter
Official title: Change in Hemogram-Derived Ratios With Sepsis Filters:A Retrospective Cohort Study in the Intensive Care Unit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Platelet Abnormality
Renal Failure
Immune System Disorder
Lead sponsor: Samsun University
Sponsor class: OTHER
First posted: 2025-04-29
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hemodiafiltration is started on patients in intensive care units. This study focuses on the change in hemogram rates in patients who underwent hemofiltration and had sepsis filters placed.

Brief summary: Hemodiafiltration is initiated in hemodynamically unstable patients in intensive care units. In some patients, additional devices called cytokine filters or sepsis filters are added to remove inflammatory cytokines. Data obtained from hemograms, such as platelet lymphocytosis ratio, are used in the diagnosis or prognosis of many diseases. This study focuses on the change in hemogram rates in patients who received hemofiltration and sepsis filters.


Eligibility criteria: Inclusion Criteria:

* Data of patients who were monitored in the Intensive Care between January 2020 and December 2022 and who were applied sepsis filters

Exclusion Criteria:

* -Patients who underwent hemodiafiltration with sepsis filter but could not be followed for 72 hours (death, etc.)

Primary outcomes:
measure: Platelet lymphocyte ratio change
timeFrame: up to 72 hours
Secondary outcomes:
measure: change in the other ratios derived from complete blood cell count
timeFrame: up to 72 hours
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istinye University
Study officials:
affiliation: Istınye university faculity of Medicine
name: Erkan Bayram
role: STUDY_CHAIR
References:
citation: Scientia et Cura: Illuminating the Dark Side. Iran J Kidney Dis. 2025 Feb 25;1(1):1.
citation: Wu D, Qin H. Diagnostic and prognostic values of immunocyte ratios in patients with sepsis in the intensive care unit. J Infect Dev Ctries. 2023 Oct 31;17(10):1362-1372. doi: 10.3855/jidc.17907.
Clinical trial NCT06753630: Polydeoxyribonucleotide for Elbow Lateral Epicondylitis
Official title: Does Combined Polydeoxyribonucleotide Improve the Outcome of Extensor Muscle Strengthening Exercise with Extracorporeal Shockwave Therapy for Lateral Epicondylitis of Elbow?: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lateral Epicondylitis
Extracorporeal Shockwave Therapy
Muscle Strengthening
Keywords: Polydeoxyribonucleotide
Lead sponsor: Chuncheon Sacred Heart Hospital
Sponsor class: OTHER
First posted: 2024-12-31
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to investigate the synergistic effect of polydeoxyribonucleotide (PDRN) on extensor muscle strengthening exercise (EMSE) combined with extracorporeal shockwave therapy (ESWT) for treating lateral epicondylitis (LE) of the elbow in adults aged 18 to 65 years. The main questions it aims to answer are:

Does the addition of PDRN improve pain reduction as measured by the Visual Analog Scale (VAS)? Does the addition of PDRN enhance functional outcomes such as the Mayo Elbow Performance Score (MEPS) and Hand Grip Strength Index (HGSI)?

Researchers will compare two groups to see if PDRN provides additional benefits:

Group 1: EMSE + ESWT + saline injection Group 2: EMSE + ESWT + PDRN injection

Participants will:

Perform extensor muscle strengthening exercises Receive extracorporeal shockwave therapy Receive either a saline injection or a PDRN injection at the first outpatient department visit Attend follow-up visits at 6 and 12 weeks for assessments


Eligibility criteria: Inclusion Criteria:

Adults aged 18 to 65 years Diagnosed with chronic lateral epicondylitis (LE) of the elbow Willing to perform extensor muscle strengthening exercises Able to attend follow-up visits at 6 and 12 weeks

Exclusion Criteria:

History of elbow surgery Significant trauma to the elbow Current use of corticosteroids for LE Current use of other treatments for LE Pregnant or breastfeeding women Participation in another clinical trial within the last 30 days

Primary outcomes:
measure: Pain Reduction
timeFrame: Baseline, 6 weeks, 12 weeks
Secondary outcomes:
measure: Functional Improvement
timeFrame: Baseline, 6 weeks, 12 weeks
measure: Grip Strength Improvement
timeFrame: Baseline, 6 weeks, 12 weeks
measure: Common Extensor Tendon Depth Measured by Ultrasonography
timeFrame: Baseline, 6 weeks, 12 weeks
measure: Color Doppler Activity Measured by Ultrasonography
timeFrame: Baseline, 6 weeks, 12 weeks
Other outcomes:
Locations:
city: Chuncheon
country: Korea, Republic of
facility: Chuncheon Sacred Heart Hospital
state: Gangwon-do
Study officials:
References:
Clinical trial NCT00191230: Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
Official title: A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma, Non Small Cell Lung
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2005-09-19
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer


Eligibility criteria: Inclusion Criteria:

* Histologically of cytologically confirmed non small cell lung cancer
* No prior chemotherapy or radiation
* No prior malignancy

Exclusion Criteria:

* Pregnant or breastfeeding
* Serious concomitant systemic disorder

Primary outcomes:
measure: Complete pathological response
Secondary outcomes:
measure: Response rate, disease free survival, toxicity including pulmonary toxicity,operative mortality and quality of life.
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
state: North Carolina
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT04439630: Effects of Nopal Fractions on Postprandial Glucose Regulation and Appetite Variables in Healthy Humans
Official title: Evaluation of Potentially Bioactive Foods With Regard to Their Effects on Cardiometabolic Test Markers and Cognitive Variables
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glucose Tolerance
Appetite Sensations
Keywords: healthy subjects
diabetes prevention
obesity prevention
Lead sponsor: Lund University
Sponsor class: OTHER
First posted: 2020-06-19
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: randomised crossover study in healthy young adults with normal BMI
Primary purpose: PREVENTION

Brief summary: Postprandial effects of Nopal fractions on glucose and appetite regulation will be investigated in healthy humans, in a randomised controlled crossover trial


Eligibility criteria: Inclusion Criteria:

* Healthy
* non-smokers
* diet accordance with the Nordic Nutrition Recommendations
* BMI: 18.5-25 kg/m2

Exclusion Criteria:

* metabolic disorders
* food allergies
* no probiotics or other food /supplement which may interfere with the study

Primary outcomes:
measure: postprandial glucose tolerance
timeFrame: 0-180 min after start of the meal
measure: postprandial insulin concentrations
timeFrame: 0-180 min
Secondary outcomes:
measure: subjective appetite variables
timeFrame: 0-180 min
Other outcomes:
Locations:
city: Lund
country: Sweden
facility: Food Technology, engineering and Nutrition, LTH, Lund University
Study officials:
affiliation: Lund University
name: Anne Nilsson, assoc. prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01500330: Home Use of Cupping Massage in Chronic Neck Pain
Official title: Randomised Controlled Study on the Effectiveness of Cupping Massage for Home Use in Chronic Neck Pain [Randomisierte Kontrollierte Studie Zur Wirksamkeit Der Schröpfkopfmassage Als Heimanwendung Bei Chronischen Nackenschmerzen]
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Lead sponsor: Universität Duisburg-Essen
Sponsor class: OTHER
First posted: 2011-12-28
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this randomized controlled study is to determine the effectiveness of cupping massage as home use for patients with chronic nonspecific neck pain compared to relaxation exercise.

Detailed description: see above

Eligibility criteria: Inclusion Criteria:

* mean neck pain intensity 45mm
* neck pain for at least 3 months
* age 18-75
* partner or friend for the application of the massage

Exclusion Criteria:

* specific neck pain due to trauma, neurological disorder, prolapse, operation, cancer
* severe deformity of the spine
* skin disease, allergy on the neck area
* hemophilia, anticoagulation, antiplatelet disorder
* severe psychiatric disorder
* severe comorbidity
* regular intake of opiates and corticosteroids \>10mg prednisolon
* pregnancy
* participation in other clinical trials

Primary outcomes:
measure: Pain Intensity
timeFrame: T2 (84 days)
Secondary outcomes:
measure: Pain diary
timeFrame: week 12
measure: pain intensity in motion
timeFrame: T2 (84 days)
measure: pain quality
timeFrame: T2 (84 days)
measure: well being
timeFrame: T2 (84 days)
measure: Quality of life
timeFrame: T2 (84 days)
measure: Stress perception
timeFrame: T2 (84 days)
measure: Control belief
timeFrame: T2 (84 days)
measure: Pressure pain threshold
timeFrame: T2 (84 days)
measure: Safety
timeFrame: T2(84 days)
Other outcomes:
Locations:
city: Essen
country: Germany
facility: Klinik für Naturheilkunde
Study officials:
affiliation: Chair of Complementary and Integrative Medicine, University Duisburg-Essen, Germany
name: Thomas Rampp, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lauche R, Materdey S, Cramer H, Haller H, Stange R, Dobos G, Rampp T. Effectiveness of home-based cupping massage compared to progressive muscle relaxation in patients with chronic neck pain--a randomized controlled trial. PLoS One. 2013 Jun 7;8(6):e65378. doi: 10.1371/journal.pone.0065378. Print 2013.
Clinical trial NCT05535530: The Effect of a Newly Designed Presurgical Orthopedic Appliance
Official title: The Effect of a Newly Designed Presurgical Orthopedic Appliance on Maxillary Arch Dimensions in Infants With Bilateral Cleft Lip and Palate: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cleft Lip and Palate
Keywords: Cleft lip and palate
Bilateral
Presurgical orthopaedic appliance
Lead sponsor: University of Baghdad
Sponsor class: OTHER
First posted: 2022-09-10
Enrollment: 30
Sex: ALL
Minimum age (years): 5
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized clinical trial to compare the effectiveness of newly designed active type of presurgical orthopedic appliances on maxillary arch dimensions in infants with bilateral cleft lip and palate.

Detailed description: It is a multicenter randomized clinical trial with two parallel arms. The patients will be randomly divided into two groups, group one: a passive orthopedic appliance will be used, and group two a new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.

Eligibility criteria: Inclusion Criteria:

* 1. Healthy new born infants with complete bilateral cleft lip, alveolus and palate.

  2. Non-syndromic. 3. Non-operated cases.

Exclusion Criteria:

* 1. Infants with systemic syndromes. 2.Facial deformities.

Primary outcomes:
measure: Arch dimension (experimental group and control group)
timeFrame: T1 before starting any treatment and T2 After treatment before surgical repair (average 3 months)
Secondary outcomes:
measure: Parents Perception and experience
timeFrame: T1 before starting any treatment and T2 After treatment before surgical repair (average 3 months)
measure: Linear measurement (experimental group and control group)
timeFrame: T1 before starting any treatment and T2 After treatment before surgical repair (average 3 months)
measure: Angular measurement (experimental group and control group)
timeFrame: T1 before starting any treatment and T2 After treatment before surgical repair (average 3 months)
measure: Vertical measurement (experimental group and control group)
timeFrame: T1 before starting any treatment and T2 After treatment before surgical repair (average 3 months)
Other outcomes:
Locations:
city: Baghdad
country: Iraq
facility: Mushreq Abed
state: Al-Rusafa
Study officials:
References:
Clinical trial NCT00225030: Observational Study of the Prognosis in Treated Arterial Hypertension
Official title: Observational Study of the Prognosis in Treated Arterial Hypertension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2005-09-23
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: NATURAL_HISTORY
Time perspective: PROSPECTIVE

Brief summary: Observational study of life time prognosis for persons medically treated for arterial hypertension, according to current WHO-guidelines.


Eligibility criteria: Inclusion Criteria:

hypertension according to WHO-defined criteria

Exclusion Criteria:

age \< 18 years

pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Medicial Dept. C, Odense University Hospital
Study officials:
name: Michael Strate, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Strate M, Vaeth M, Harvald B. Twenty-one-year survival of primary hypertensive patients allocated to care in general practice or in specialized hypertension clinic. An observational study of 831 hypertensive patients. Blood Press. 1997 Mar;6(2):88-95. doi: 10.3109/08037059709061805.
Clinical trial NCT05224830: Relationship Between Hyperventilation Syndrome and SARS-CoV-2 Infection
Official title: A Cross-sectional Study : Is There a Relationship Between Hyperventilation Syndrome and History of Acute SARS-CoV-2 Infection?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Hyperventilation Syndrome
Keywords: covid-19
dyspnea
Hyperventilation Syndrome
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2022-02-04
Enrollment: 2846
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The inclusion criteria were age greater than 18 years old, with the ability to perform a pulmonary function test in our Lung Function and Exercise Testing Department. Eligible patients were able to read and speak French in order to correctly answer to the self-reported questionnaire. The exclusion criteria were incomplete questionnaire or inability to obtain an interpretable lung function assessment.

Brief summary: Following an acute COVID-19 infection, many patients suffer from long lasting physical symptoms that may greatly impair quality of life. Persisting dyspnea and other functional respiratory complaints could evoke Hyperventilation Syndrome (HVS) as a putative contributor of the long-COVID presentation in COVID-19 survivors. We aimed to assess the possible relationship between a HVS and previous acute SARS-CoV-2 infection.


Eligibility criteria: Inclusion Criteria:

* Read and speak French
* Perform a pulmonary function test

Exclusion Criteria:

- incomplete questionnaire or inability to obtain an interpretable lung function assessment

Primary outcomes:
measure: Assess the relationship between a hyperventilation syndrome and previous acute SARS-CoV-2 infection.
timeFrame: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
Secondary outcomes:
measure: Assess the relationship between a hyperventilation syndrome and dyspnea
timeFrame: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
Other outcomes:
Locations:
city: Vandoeuvre les nancy
country: France
facility: Centre Hospitalier Régional Universitaire de Nancy.
Study officials:
References:
Clinical trial NCT02238730: Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
Official title: Comparative Efficacy and Cognitive Side-Effects of Ultrabrief Right Unilateral Electroconvulsive Therapy and Brief Pulse Bitemporal Electroconvulsive Therapy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Depression
Depressive Disorder
Treatment Resistant Depressive Disorder
Bipolar Disorder
Major Depressive Disorder
Keywords: Depression
Depressive Disorder
Treatment Resistant Depressive Disorder
Bipolar Disorder
Major Depressive Disorder
Electroconvulsive therapy
Lead sponsor: Kaiser Permanente
Sponsor class: OTHER
First posted: 2014-09-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the equivalent efficacy of ultrabrief pulsewidth right unilateral electroconvulsive therapy versus bitemporal brief pulse electroconvulsive therapy in the treatment of depression and to evaluate the cognitive effects of ultrabrief right unilateral electroconvulsive therapy versus bitemporal brief pulse electroconvulsive therapy.

Detailed description: Patients will be randomized to either bitemporal brief pulse electroconvulsive therapy ( 0.5 ms pulse width) or right unilateral ultrabrief pulse electroconvulsive therapy for the first six treatments. If further treatment is necessary, electrode placement will be chosen by the treating psychiatrist. All electroconvulsive therapy treatments will be performed with a Thymatron System IV instrument. (Somatics, LLC, Lake Bluff, Illinois, USA) Pre- electroconvulsive therapy testing will occur within one week of beginning treatment. Post-electroconvulsive therapy testing will occur within 48 hours of the 6th treatment.

Eligibility criteria: Inclusion Criteria:

* All patients age 18 and above referred for electroconvulsive therapy will be screened for eligibility for participation in this study.
* Basic competency in English
* Diagnosis of either of the following:

  1. Major Depressive Disorder, Single Episode
  2. Major Depressive Disorder, Recurrent
  3. Bipolar Disorder, Currently Depressed

Exclusion Criteria:

* Pre-existing cognitive impairment with an initial Mini Mental Status Exam Score of 24 or lower
* Major neurological disease
* Other medical conditions making electroconvulsive therapy an excessive risk to be completed safely in an outpatient surgery center and anticonvulsant therapy.
* Pregnancy

Primary outcomes:
measure: Hamilton Depression Rating Scale (HAMD)
timeFrame: up to 2-3 weeks
Secondary outcomes:
measure: Mini Mental Status Examination
timeFrame: up to 2-3 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Kaiser Permanente
name: Ronad L Warnell, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03017430: Pregabalin for Opiate Withdrawal Syndrome
Official title: Randomized Clinical Trial of Pregabalin for Opioid Withdrawal Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Opioid Withdrawal
Lead sponsor: St. Petersburg Bekhterev Research Psychoneurological Institute
Sponsor class: OTHER
First posted: 2017-01-11
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is a single blind randomized symptom triggered study to assess efficacy and safety of pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs. clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.

Detailed description: Study design: Single-blind randomized symptom-regulated protocol with an active control. Eighty patients admitted to an inpatient addiction treatment program will be randomly assigned to two groups. The first group (N=40) receives up to 600 mg a day of Pregabalin for six days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine). The second group (N= 40) receives up to 600 micrograms of Clonidine a day as the main treatment along with the same basic and symptomatic regimen. Opiate withdrawal severity, craving, sleep disturbance, anxiety and depression, as well as general clinical impressions and side effects are assessed daily by psychiatrists who are blind to patients' group assignment using internationally validated quantitative psychometric instruments.

Eligibility criteria: Inclusion Criteria:

* Opioid Use Disorders; Opioid Withdrawal Syndrome

Exclusion Criteria:

* Severe psychiatric and somatic disorders, other Substance Use Disorders (except tobacco)

Primary outcomes:
measure: Number of patients completed detoxification
timeFrame: 7 days
Secondary outcomes:
measure: Severity of opiod withdrawal
timeFrame: 7 days
measure: Amount of Ketorolac administered
timeFrame: 7 days
measure: Number and severity of adverse events
timeFrame: 7 days
Other outcomes:
measure: Craving for opiates
timeFrame: 7 days
Locations:
city: St.-Petersburg
country: Russian Federation
facility: St.-Petersburg Bekhterev Reserach Psychoneurological Institute
Study officials:
References: